Compare USFD & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USFD | INCY |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 17.0B |
| IPO Year | 2016 | 1993 |
| Metric | USFD | INCY |
|---|---|---|
| Price | $86.80 | $101.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $89.70 | ★ $97.78 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 02-12-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.09 | ★ 3878.02 |
| EPS | 2.38 | ★ 5.90 |
| Revenue | ★ $39,115,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $6.50 | $19.64 |
| Revenue Next Year | $6.20 | $10.98 |
| P/E Ratio | $36.87 | ★ $17.10 |
| Revenue Growth | 4.80 | ★ 18.09 |
| 52 Week Low | $57.36 | $53.56 |
| 52 Week High | $88.32 | $112.29 |
| Indicator | USFD | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 48.35 |
| Support Level | $82.51 | $99.28 |
| Resistance Level | $88.32 | $104.41 |
| Average True Range (ATR) | 2.22 | 3.12 |
| MACD | 0.32 | -0.47 |
| Stochastic Oscillator | 76.38 | 29.50 |
US Foods Holding Corp is the U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. It has nearly 250,000 restaurants and foodservice operators with more than 70 locations that provide customers with food offering and a comprehensive suite of e-commerce, technology, and business solutions. The company operates in one business segment in which it markets, sells and distributes fresh, frozen and dry food and non-food products to foodservice customers throughout the U.S.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.